Pazopanib eye drops: a randomised trial in neovascular age-related macular degeneration.
OBJECTIVE
To evaluate pazopanib eye drops in patients with subfoveal choroidal neovascularisation secondary to age-related macular degeneration.


METHODS
70 patients with minimally classic or occult subfoveal choroidal neovascularisation were randomly assigned to 5 mg/mL TID, 2 mg/mL TID, and 5 mg/mL QD pazopanib eye drops for 28 days in a multicentre, double-masked trial with an optional safety extension for up to 5 additional months. The primary outcomes were central retinal thickness (CRT) and best-corrected visual acuity (BCVA) at Day 29.


RESULTS
No significant decrease from baseline in CRT was observed overall; however, an exploratory analysis showed improvement in CRT (mean decrease of 89 μm) in patients with the CFH TT genotype who received 5 mg/mL TID (p=0.01, n=5). Mean increases in BCVA were observed in the 5 mg/mL TID overall (4.32 letters (p=0.002, n=26)) and in those that with CFH Y402H TT (6.96 letters (p=0.02, n=5)) and CT (4.09 letters (p=0.05, n=9)) genotypes. No safety signals that precluded continued investigation were detected.


CONCLUSIONS
5 mg/mL pazopanib eye drops resulted in mean improvement in BCVA at Day 29 and improvements in vision. However, improvement in macular oedema for age-related macular degeneration was found only in the subset of subjects with the CFH Y402H TT genotype, warranting further investigation.
Department of Ophthalmology and Visual Sciences, University of Wisconsin-Madison School of Medicine and Public Health, , Madison, Wisconsin, USA.
Ronald
R
Danis
Megan M
MM
McLaughlin
Michael
M
Tolentino
Giovanni
G
Staurenghi
Li
L
Ye
Chun-Fang
CF
Xu
Robert Y
RY
Kim
Mark W
MW
Johnson
D020533:Angiogenesis Inhibitors; D020256:Choroidal Neovascularization / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007191:Indazoles; D008268:Macular Degeneration / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions; D011446:Prospective Studies; D011743:Pyrimidines / Q000008:administration & dosage* / Q000493:pharmacokinetics; D013449:Sulfonamides / Q000008:administration & dosage* / Q000493:pharmacokinetics; D016896:Treatment Outcome; D014792:Visual Acuity
D020533:Angiogenesis Inhibitors; D007191:Indazoles; D009883:Ophthalmic Solutions; D011743:Pyrimidines; D013449:Sulfonamides; C516667:pazopanib
Clinical Trial; Diagnostic tests/Investigation; Drugs; Macula; Neovascularisation